DEDICA (Dose of HEparin During Coronary Angioplasty) Trial
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
International guidelines support the use of a full-dose heparin (anticoagulants) during
coronary intervention. However, a lower dose of heparin may be adequate, thanks to advances
in angioplasty techniques and the widespread use of pretreatment with two antiplatelet
agents.
Thus the investigators designed a study comparing safety and efficacy of standard dose
heparin (100 UI/Kg) versus low-dose (50 UI/Kg) in patients undergoing coronary angioplasty
who are on aspirin and clopidogrel at the time of the procedure.